Concentra Group Holdings Parent, Inc. (CON) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $6.2M sold). Latest close $41.98 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 17, 2026 · Congress to Nov 16, 2026.
First Eagle Investment Management — 1 tracked fund hold CON. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 6 sales ($6.2M). Insider trading
Acadia Healthcare Company, Inc. (ACHC) · HCA Healthcare, Inc. (HCA) · Natera, Inc. (NTRA) · Guardant Health, Inc. (GH) · Brookdale Senior Living Inc. (BKD) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| First Eagle Investment Management | 0.03% | 648,059 | ADDED (+62.1%) Q3 filed Nov 10 |
| Maverick Capital | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +37.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 288 of 8,857 filers |
| Long-only filers among them | 288 |
| Change vs 2026 Q1 | +18 net · 281 entered · 263 exited |
| Shares reported, all filers | 111,242,382 |
| Reported value, all filers | $2.6B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Services-Specialty Outpatient Facilities, NEC (SIC 8093) |
| Revenue · FY2025 | $2.2B |
| Net income · FY2025 | $166.4M |
| Total assets · FY2025 | $2.9B |
| Shares outstanding | 127,517,736 |
| Market cap (at latest close) | $5.4B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Oct 15, 2026 | 3,601,334 |
| Share of shares outstanding | 2.82% |
| Days to cover | 2.87 |
Shares short at recent settlements — Jul 31, 2026: 3.1M · Aug 14, 2026: 2.2M · Aug 31, 2026: 2.8M · Sep 15, 2026: 3.2M · Sep 30, 2026: 3.6M · Oct 15, 2026: 3.6M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 3K · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 6 sales by 6 insiders ($6.2M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 17, 2026 | deLorimier John A. | See Remarks | Sell | 17,444 | $42.87 | $747.7K | SEC filing |
| Nov 17, 2026 | Newton Raymond Tanner | EVP & Chief Financial Officer | Sell | 2,843 | $42.93 | $122.0K | SEC filing |
| Nov 16, 2026 | Newton William Keith | Sell | 68,232 | $43.13 | $2.9M | SEC filing | |
| Nov 16, 2026 | Devasia Thomas A. | See Remarks | Sell | 18,194 | $42.92 | $781.0K | SEC filing |
| Nov 12, 2026 | Gilbert Greg M. | See Remarks | Sell | 18,194 | $42.90 | $780.5K | SEC filing |
| Nov 12, 2026 | Conser Jonathan P. | See Remarks | Sell | 18,194 | $42.99 | $782.2K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | ORTENZIO ROBERT A | Director | 130,000 | $4.1M | Aug 3, 2026 | SEC filing |
| Jul 1, 2026 | ORTENZIO ROBERT A | Director | 389,940 | $15.9M | Jul 1, 2026 | SEC filing |
| Jun 30, 2026 | ORTENZIO ROBERT A | Director | 944 | $27.8K | Jun 30, 2026 | SEC filing |
| Jun 29, 2026 | ORTENZIO ROBERT A | Director | 5,589 | $166.8K | Jun 29, 2026 | SEC filing |
| Jun 26, 2026 | ORTENZIO ROBERT A | Director | 53,527 | $1.6M | Jun 26, 2026 | SEC filing |
| Jun 26, 2026 | ORTENZIO ROBERT A | Director | 53,527 | $1.6M | Jun 26, 2026 | SEC filing |
| Jun 1, 2026 | ORTENZIO ROBERT A | Chairman | 130,000 | $3.2M | Jun 1, 2026 | SEC filing |
| May 8, 2026 | ORTENZIO ROBERT A | Chairman | 130,000 | $3.2M | May 8, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Sep 1, 2026 | SCHEDULE 13D/A | +24.5% (close Sep 2, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Sep 2, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Robert A. Ortenzio | SC 13D/A | 6,648,222 | 5.2% | Sep 1, 2026 | SEC filing |
| Aug 24, 2026 | Robert A. Ortenzio | SC 13D/A | 6,748,222 | 5.3% | Aug 21, 2026 | SEC filing |
| Jul 27, 2026 | BlackRock, Inc. | SC 13G/A | 17,569,590 | 13.7% | Jun 30, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Portfolio Management | SC 13G | 6,837,148 | 5.3% | Mar 31, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 17, 2026 | T. Rowe Price Associates, Inc. | SC 13G/A | 16,843,425 | 13.1% | Dec 31, 2025 | SEC filing |
| Nov 26, 2025 | ORTENZIO ROBERT A | SC 13D/A | 8,168,222 | 6.4% | Nov 25, 2025 | SEC filing |
| Nov 14, 2025 | T. Rowe Price Investment Management, Inc. | SC 13G/A | 6,267,949 | 4.9% | Sep 30, 2025 | SEC filing |
| Nov 14, 2025 | T. Rowe Price Associates, Inc. | SC 13G/A | 17,166,753 | 13.4% | Sep 30, 2025 | SEC filing |
| Jul 7, 2025 | The Vanguard Group | SC 13G/A | 13,177,363 | 10.3% | Jun 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Services-Specialty Outpatient Facilities, NEC (SIC 8093). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Financial Screens
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.54 · Operating cash flow: $279.4M · Net income: $166.4M
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold CON — ranked by lift, the co-holding pattern described in Methodology: Acadia Healthcare Company, Inc. (ACHC) · HCA Healthcare, Inc. (HCA) · Natera, Inc. (NTRA) · Guardant Health, Inc. (GH) · Brookdale Senior Living Inc. (BKD) · LABCORP HOLDINGS INC. (LH) · RadNet, Inc. (RDNT) · BrightSpring Health Services, Inc. (BTSG).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 10, 2026 | 1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits | SEC filing |
| Nov 9, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers | SEC filing |
| Nov 5, 2026 | 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Acadia Healthcare Company, Inc. (ACHC) · Track Record: how the signals scored · Practice timing on CON
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.